"","study ID","first author","study design","publication date","primary series vaccine","historyofCOVID","dose_number","dose","timing_of_dose_days","outcome_detail","outcome_category","country","population_detail","population_category","VE","LCL","UCL","variant_sequenced","variant_context","max duration follow-up","dose interval","notes","n_row","country_clean","iso3c","Study_id_f","Country.Code","GNI_per_c_WB","year_GNI","Economy","Region","Income group","q_GNI_per_c_WB","continent","owid_vac_intro","owid_vac_F40","owid_vac_F70","who_vac_intro","min_vac_intro","diff_owid_who_intro","diff_intro_F40","diff_intro_F70","V1_date_group","V40_date_group","V40_group","V1_dummy","V40_dummy","V70_dummy","publication_date","outcome_final","semester","clean_vaccine","vac_type","variant_clean","include_population","inclusion_notes","clean_vaccine_dose","max_follow_up_days","n_estimates"
"1",43,"Stowe","Test-negative case-control","14June2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","UK","hospital patients","general pop",96,86,99,"delta","delta","~20 weeks",NA,NA,191,"UK","GBR",43,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",140,1
"2",49,"Nasreen","Test-negative case-control","07Feb2022","BNT162b2 (Pfizer BioNTech)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",98,96,99,"delta","delta","~28 weeks",NA,NA,277,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",196,1
"3",74,"Tang","Test-negative case-control","02Nov2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",94.1,85.9,97.6,"delta","delta","~25 weeks",NA,NA,444,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",175,1
"4",80,"Tartof","Retrospective cohort","16Oct2021","BNT162b2 (Pfizer BioNTech)","included","2","final","7+","hospitalization","severe","USA",">= 12 years","general pop",93,84,96,"delta","delta","~29 weeks",NA,NA,515,"USA","USA",80,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-16,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",203,1
"5",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-203","severe disease","severe","Israel","40-59 years","40-59 years",98,94,99,NA,"delta","28 weeks",NA,NA,528,"Israel","ISR",81,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-27,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",196,4
"6",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","168-203","severe disease","severe","Israel",">= 60 years",">= 60 years",93,86,97,NA,"delta","13 weeks",NA,NA,529,"Israel","ISR",81,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-27,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",91,4
"7",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","109-159","severe disease","severe","Israel","40-59 years","40-59 years",92,87,95,NA,"delta","22 weeks",NA,NA,530,"Israel","ISR",81,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-27,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",154,4
"8",81,"Golberg","Retrospective cohort","27Oct2021","BNT162b2 (Pfizer BioNTech)","excluded","2","final","109-159","severe disease","severe","Israel",">= 60 years",">= 60 years",85,81,88,NA,"delta","22 weeks",NA,NA,531,"Israel","ISR",81,"ISR",43800,2019,"Israel","Middle East & North Africa","High income",4,"Asia",2020-12-20,2021-03-07,NA,2020-12-16,2020-12-16,4,81,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2021-10-27,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",154,4
"9",92,"Grannis","Test-negative case-control","10Sept2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",80,73,85,NA,"delta","4 weeks",NA,NA,609,"USA","USA",92,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",28,1
"10",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","UK",">= 16 years","general pop",96.6,96.2,96.9,"delta","delta","~33.5 weeks",NA,NA,649,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",234.5,3
"11",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-69","hospitalization","severe","UK",">= 16 years","general pop",98.4,97.9,98.8,"delta","delta","~8 weeks",NA,NA,650,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",56,3
"12",95,"Andrews","Test-negative case-control","12Jan2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","140+","hospitalization","severe","UK",">= 16 years","general pop",92.7,90.3,94.6,"delta","delta","~33.5 weeks",NA,NA,651,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",234.5,3
"13",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Canada",">= 18 years","general pop",98,97,98,"delta","delta","~38 weeks",NA,NA,934,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",266,3
"14",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-27","hospitalization","severe","Canada",">= 18 years","general pop",98,95,99,"delta","delta","~38 weeks",NA,NA,935,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",266,3
"15",114,"Skowronski","Test-negative case-control","19Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","196-223","hospitalization","severe","Canada",">= 18 years","general pop",94,87,97,"delta","delta","~38 weeks",NA,NA,936,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",266,3
"16",151,"Collie","Test-negative case-control","29Dec2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","Hospitalization","severe","South Africa",">= 18 years","general pop",93,90,94,NA,"delta","~19 weeks",NA,NA,1296,"South Africa","ZAF",151,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"feb/2021","not reached","not reached","yes","no","no",2021-12-29,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",133,1
"17",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","hospitalization","severe","USA","hospital admissions","general pop",76,69,82,"delta","delta","~47 weeks",NA,NA,1396,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",329,3
"18",166,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 to <3 months","hospitalization","severe","USA","hospital admissions","general pop",78,55,89,"delta","delta","~47 weeks",NA,NA,1397,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",329,3
"19",167,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">=9 months","hospitalization","severe","USA","hospital admissions","general pop",73,58,83,"delta","delta","~47 weeks",NA,NA,1398,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",329,3
"20",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","intubation","severe","Greece","15-59 years","15-59 years",98.1,97.5,98.6,NA,"delta","~48 weeks",NA,NA,1432,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",336,6
"21",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","6 months","intubation","severe","Greece","15-59 years","15-59 years",95.5,94.3,96.5,NA,"delta","~48 weeks",NA,NA,1433,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",336,6
"22",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","intubation","severe","Greece","60-79 years","60-79 years",96.7,95.9,97.4,NA,"delta","~48 weeks",NA,NA,1434,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",336,6
"23",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","6 months","intubation","severe","Greece","60-79 years","60-79 years",92,91,92.9,NA,"delta","~48 weeks",NA,NA,1435,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",336,6
"24",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","intubation","severe","Greece",">= 80 years",">= 80 years",94.2,92,95.7,NA,"delta","~48 weeks",NA,NA,1436,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",336,6
"25",174,"Lytras","Retrospective cohort","14Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","6 months","intubation","severe","Greece",">= 80 years",">= 80 years",85.9,83.5,88,NA,"delta","~48 weeks",NA,NA,1437,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",336,6
"26",178,"Lauring","Test-negative case-control","09Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",82,80,84,"delta","delta","~27 weeks",NA,NA,1518,"USA","USA",178,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",189,1
"27",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",80,72,85,NA,"delta","~54 weeks",NA,NA,1646,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",378,2
"28",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",82,77,86,NA,"delta","~54 weeks",NA,NA,1648,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",378,2
"29",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",90,78,96,NA,"delta","~48.5 weeks",NA,NA,1773,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",339.5,2
"30",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",79,71,84,NA,"delta","~48.5 weeks",NA,NA,1774,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",339.5,2
"31",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","2-9 weeks","hospitalization","severe","Norway",">= 18 years","general pop",97.5,95.6,98.6,NA,"delta","~7 weeks",NA,NA,1921,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",49,2
"32",218,"Starrfelt","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">33 weeks","hospitalization","severe","Norway",">= 18 years","general pop",63.9,54.3,71.5,NA,"delta","~43 weeks",NA,NA,1922,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",301,2
"33",230,"Plumb","Test-negative case-control","12Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",50,39,59,NA,"delta","~55 weeks",NA,NA,1986,"USA","USA",230,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",385,1
"34",235,"Voko","Retrospective cohort","22Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-120","hospitalization","severe","Hungary","18-64 years","18-64 years",82.6,80.1,84.7,NA,"delta","~47 weeks",NA,NA,2037,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",329,2
"35",235,"Voko","Retrospective cohort","22Jul2022","BNT162b2 (Pfizer BioNTech)","included","2","final","240+","hospitalization","severe","Hungary","18-64 years","18-64 years",69.6,64.9,73.6,NA,"delta","~47 weeks",NA,NA,2038,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",329,2
"36",310,"Penayo","Test-negative case-control","01Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",91.9,72.2,97.6,NA,"delta","~38 weeks",NA,NA,2612,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",266,1
"37",311,"Monge","Case cohort","02Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","Spain","50-59 years","50-59 years",97,97,98,NA,"delta","~21 weeks",NA,NA,2628,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",147,1
"38",315,"Chatzilena","Test-negative case-control","07Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","hospitalization","severe","UK",">=18 years","general pop",82.5,76.2,87.2,NA,"delta","~56 weeks",NA,NA,2653,"UK","GBR",315,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",392,3
"39",315,"Chatzilena","Test-negative case-control","07Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">=3 months","hospitalization","severe","UK",">=18 years","general pop",91.5,83.1,96.2,NA,"delta","~56 weeks",NA,NA,2654,"UK","GBR",315,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",392,3
"40",315,"Chatzilena","Test-negative case-control","07Dec2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">3 months","hospitalization","severe","UK",">=18 years","general pop",79.5,71.5,85.3,NA,"delta","~56 weeks",NA,NA,2655,"UK","GBR",315,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",392,3
"41",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~25 weeks","hospitalization","severe","USA",">=5 years","general pop",85.8,83.4,87.8,NA,"delta","~25 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2751,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",175,2
"42",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~38 weeks","hospitalization","severe","USA",">=5 years","general pop",70.9,65.3,75.6,NA,"delta","~38 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2752,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",266,2
"43",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-149","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",90,88,91,NA,"delta","~46 weeks",NA,NA,2859,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",322,2
"44",336,"Embi","Test-negative case-control","22May2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",80,79,82,NA,"delta","~46 weeks",NA,NA,2860,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",322,2
"45",387,"Altarawneh","Test-negative case-control","27Jul2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe, critical or fatal disease","severe","Qatar","all ages","general pop",91.1,86.3,94.2,NA,"delta","~48 weeks",NA,NA,3289,"Qatar","QAT",387,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-27,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",336,1
"46",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",91,79,96,NA,"delta","~36 weeks",NA,NA,3543,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",252,1
"47",422,"Mimura","Retrospective cohort","23Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","hospitalization","severe","Japan",">=65 years",">=65 years",93.5,83.7,100,NA,"delta","~22 weeks",NA,NA,3576,"Japan","JPN",422,"JPN",41970,2019,"Japan","East Asia & Pacific","High income",4,"Asia",2021-02-22,2021-08-11,2021-10-16,2021-02-17,2021-02-17,5,175,241,"feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-09-23,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",154,1
"48",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<91","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",87.5,84.9,89.7,NA,"delta","~33 weeks",NA,NA,3588,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",231,4
"49",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","141+","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",80.5,77.4,83.2,NA,"delta","~33 weeks",NA,NA,3589,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",231,4
"50",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","<91","severe disease","severe","Mexico",">=65 years",">=65 years",90.4,87.8,92.4,NA,"delta","~33 weeks",NA,NA,3590,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",231,4
"51",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","141+","severe disease","severe","Mexico",">=65 years",">=65 years",85.3,82.3,87.8,NA,"delta","~33 weeks",NA,NA,3591,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","delta","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",231,4
"52",49,"Nasreen","Test-negative case-control","07Feb2022","mRNA-1273 (Moderna)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",98,93,100,"delta","delta","~25 weeks",NA,NA,281,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",175,1
"53",74,"Tang","Test-negative case-control","02Nov2021","mRNA-1273 (Moderna)","included","2","final","14+","severe, critical, fatal disease","severe","Qatar","general pop","general pop",96.1,71.4,99.5,"delta","delta","~25 weeks",NA,NA,446,"Qatar","QAT",74,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"jan/2021","before Jun/2021","<180","yes","yes","yes",2021-11-02,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",175,1
"54",92,"Grannis","Test-negative case-control","10Sept2021","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",95,92,97,NA,"delta","4 weeks",NA,NA,611,"USA","USA",92,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2021-09-10,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",28,1
"55",95,"Andrews","Test-negative case-control","12Jan2022","mRNA-1273 (Moderna)","excluded","2","final","14-69","hospitalization","severe","UK",">= 16 years","general pop",100,NA,NA,"delta","delta","~7 weeks",NA,NA,673,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",49,1
"56",104,"Bruxvoort","Test-negative case-control","15Dec2021","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",97.5,92.7,99.2,"delta","delta","~25 weeks",NA,NA,801,"USA","USA",104,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2021-12-15,"severe","2021 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",175,1
"57",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Canada",">= 18 years","general pop",97,97,98,"delta","delta","~38 weeks",NA,NA,940,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",266,3
"58",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14-27","hospitalization","severe","Canada",">= 18 years","general pop",98,94,100,"delta","delta","~38 weeks",NA,NA,941,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",266,3
"59",114,"Skowronski","Test-negative case-control","19Apr2022","mRNA-1273 (Moderna)","excluded","2","final","196-223","hospitalization","severe","Canada",">= 18 years","general pop",95,80,99,"delta","delta","~38 weeks",NA,NA,942,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",266,3
"60",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","Hospitalization","severe","USA",">= 18 years","general pop",99,93.3,99.9,"delta","delta","~47.5 weeks",NA,NA,1355,"USA","USA",159,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-21,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",332.5,1
"61",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","intubation","severe","Greece","15-59 years","15-59 years",99.4,98.2,99.8,NA,"delta","~48 weeks",NA,NA,1444,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",336,6
"62",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","6 months","intubation","severe","Greece","15-59 years","15-59 years",97.3,93.1,98.9,NA,"delta","~48 weeks",NA,NA,1445,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",336,6
"63",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","intubation","severe","Greece","60-79 years","60-79 years",98.9,97.3,99.5,NA,"delta","~48 weeks",NA,NA,1446,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",336,6
"64",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","6 months","intubation","severe","Greece","60-79 years","60-79 years",95.1,93,96.5,NA,"delta","~48 weeks",NA,NA,1447,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",336,6
"65",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","intubation","severe","Greece",">= 80 years",">= 80 years",97.9,90.2,99.5,NA,"delta","~48 weeks",NA,NA,1448,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",336,6
"66",174,"Lytras","Retrospective cohort","14Jun2022","mRNA-1273 (Moderna)","included","2","final","6 months","intubation","severe","Greece",">= 80 years",">= 80 years",90.6,67,97.3,NA,"delta","~48 weeks",NA,NA,1449,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",336,6
"67",178,"Lauring","Test-negative case-control","09Mar2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",88,86,90,"delta","delta","~27 weeks",NA,NA,1519,"USA","USA",178,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-03-09,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",189,1
"68",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",100,NA,NA,NA,"delta","~54 weeks",NA,NA,1654,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",378,2
"69",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",82,78,85,NA,"delta","~54 weeks",NA,NA,1656,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",378,2
"70",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",92,42,99,NA,"delta","~48.5 weeks",NA,NA,1777,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",339.5,2
"71",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",87,70,94,NA,"delta","~48.5 weeks",NA,NA,1778,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",339.5,2
"72",218,"Starrfelt","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","2","final","18-25 weeks","hospitalization","severe","Norway",">= 18 years","general pop",95.3,91.5,97.4,NA,"delta","~23 weeks",NA,NA,1927,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",161,2
"73",218,"Starrfelt","Retrospective cohort","30Mar2022","mRNA-1273 (Moderna)","excluded","2","final","26-33 weeks","hospitalization","severe","Norway",">= 18 years","general pop",91.1,84.9,94.8,NA,"delta","~31 weeks",NA,NA,1928,"Norway","NOR",218,"NOR",82430,2019,"Norway","Europe & Central Asia","High income",4,"Europe",2020-12-28,2021-08-12,2021-11-18,2020-12-23,2020-12-23,5,232,330,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",217,2
"74",230,"Plumb","Test-negative case-control","12Apr2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",44,29.9,55.2,NA,"delta","~55 weeks",NA,NA,1987,"USA","USA",230,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",385,1
"75",235,"Voko","Retrospective cohort","22Jul2022","mRNA-1273 (Moderna)","included","2","final","14-120","hospitalization","severe","Hungary","18-64 years","18-64 years",84.9,75.4,90.8,NA,"delta","~47 weeks",NA,NA,2043,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",329,2
"76",235,"Voko","Retrospective cohort","22Jul2022","mRNA-1273 (Moderna)","included","2","final","240+","hospitalization","severe","Hungary","18-64 years","18-64 years",42.5,-4,68.2,NA,"delta","~47 weeks",NA,NA,2044,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",329,2
"77",310,"Penayo","Test-negative case-control","01Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",76.1,-127.4,97.5,NA,"delta","~37 weeks",NA,NA,2613,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",259,1
"78",311,"Monge","Case cohort","02Sept2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","Spain","50-59 years","50-59 years",98,97,99,NA,"delta","~21 weeks",NA,NA,2632,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",147,1
"79",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~24 weeks","hospitalization","severe","USA",">=5 years","general pop",89.8,88.1,91.3,NA,"delta","~24 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2757,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",168,2
"80",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~37 weeks","hospitalization","severe","USA",">=5 years","general pop",72.7,67.8,77,NA,"delta","~37 weeks",NA,"Note: this study includes additional VE estimates for individuals vaccinated during different time periods",2758,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",259,2
"81",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","14-149","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",95,92,95,NA,"delta","~46 weeks",NA,NA,2857,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",322,2
"82",336,"Embi","Test-negative case-control","22May2023","mRNA-1273 (Moderna)","included","2","final","150+","hospitalization with COVID-like illness","severe","USA","immunocompetent adults >=18 years","immunocompetent adults",89,88,90,NA,"delta","~46 weeks",NA,NA,2858,"USA","USA",336,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2023-05-22,"severe","2023 (Jan-Jun)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",322,2
"83",387,"Altarawneh","Test-negative case-control","27Jul2023","mRNA-1273 (Moderna)","excluded","2","final","14+","severe, critical or fatal disease","severe","Qatar","all ages","general pop",97.9,91.2,99.5,NA,"delta","~48 weeks",NA,NA,3291,"Qatar","QAT",387,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"jan/2021","before Jun/2021","<180","yes","yes","yes",2023-07-27,"severe","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","delta","yes",NA,"Moderna mRNA-1273 x 2",336,1
"84",43,"Stowe","Test-negative case-control","14June2021","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization","severe","UK","hospital patients","general pop",92,75,97,"delta","delta","~20 weeks",NA,NA,193,"UK","GBR",43,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-06-14,"severe","2021 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",140,1
"85",49,"Nasreen","Test-negative case-control","07Feb2022","AZD1222 (AstraZeneca)","unknown","2","final","14+","hospitalization or death","severe","Canada","general pop","general pop",90,67,97,"delta","delta","~3 weeks",NA,NA,285,"Canada","CAN",49,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-02-07,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",21,1
"86",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","UK",">= 16 years","general pop",92.5,92,93,"delta","delta","~20.5 weeks",NA,NA,661,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",143.5,3
"87",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","14-69","hospitalization","severe","UK",">= 16 years","general pop",95.2,94.6,95.6,"delta","delta","~8 weeks",NA,NA,662,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",56,3
"88",95,"Andrews","Test-negative case-control","12Jan2022","AZD1222 (AstraZeneca)","excluded","2","final","140+","hospitalization","severe","UK",">= 16 years","general pop",77,70.3,82.3,"delta","delta","~20.5 weeks",NA,NA,663,"UK","GBR",95,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-01-12,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",143.5,3
"89",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","14+","Hospitalization","severe","Canada",">= 18 years","general pop",95,93,97,"delta","delta","~38 weeks",NA,NA,946,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",266,3
"90",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","28-55","Hospitalization","severe","Canada",">= 18 years","general pop",89,67,97,"delta","delta","~38 weeks",NA,NA,947,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",266,3
"91",114,"Skowronski","Test-negative case-control","19Apr2022","AZD1222 (AstraZeneca)","excluded","2","final","168-195","Hospitalization","severe","Canada",">= 18 years","general pop",91,34,99,"delta","delta","~38 weeks",NA,NA,948,"Canada","CAN",114,"CAN",46580,2019,"Canada","North America","High income",4,"North America",2020-12-16,2021-07-09,2021-09-28,2020-12-14,2020-12-14,2,207,288,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-04-19,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",266,3
"92",146,"Katikireddi","Retrospective cohort","20Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","14-27","severe disease","severe","Scotland",">= 18 years","general pop",83.7,79.7,87,NA,"delta","~20 weeks",NA,NA,1281,"UK","GBR",146,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-20,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",140,2
"93",146,"Katikireddi","Retrospective cohort","20Dec2021","AZD1222 (AstraZeneca)","excluded","2","final","140-153","severe disease","severe","Scotland",">= 18 years","general pop",53.6,48.4,58.3,NA,"delta","~20 weeks",NA,NA,1282,"UK","GBR",146,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2021-12-20,"severe","2021 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",140,2
"94",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","intubation","severe","Greece","15-59 years","15-59 years",97.8,95.3,99,NA,"delta","~48 weeks",NA,NA,1456,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",336,6
"95",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","6 months","intubation","severe","Greece","15-59 years","15-59 years",92.4,84,96.4,NA,"delta","~48 weeks",NA,NA,1457,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",336,6
"96",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","intubation","severe","Greece","60-79 years","60-79 years",97.2,95.3,98.3,NA,"delta","~48 weeks",NA,NA,1458,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",336,6
"97",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","6 months","intubation","severe","Greece","60-79 years","60-79 years",90.3,87.4,92.5,NA,"delta","~48 weeks",NA,NA,1459,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",336,6
"98",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","intubation","severe","Greece",">= 80 years",">= 80 years",97.8,91.7,99.4,NA,"delta","~48 weeks",NA,NA,1460,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",336,6
"99",174,"Lytras","Retrospective cohort","14Jun2022","AZD1222 (AstraZeneca)","included","2","final","6 months","intubation","severe","Greece",">= 80 years",">= 80 years",92.4,72.7,97.9,NA,"delta","~48 weeks",NA,NA,1461,"Greece","GRC",174,"GRC",19690,2019,"Greece","Europe & Central Asia","High income",3,"Europe",2020-12-29,2021-07-09,2022-01-24,2020-12-23,2020-12-23,6,198,397,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-06-14,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",336,6
"100",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","75-135","hospitalization","severe","Czech Republic","all ages","general pop",80,62,89,NA,"delta","~54 weeks",NA,NA,1659,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",378,2
"101",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",68,64,71,NA,"delta","~54 weeks",NA,NA,1660,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",378,2
"102",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","91-180","hospitalization","severe","Finland",">= 70 years",">= 70 years",79,67,87,NA,"delta","~48.5 weeks",NA,NA,1780,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",339.5,2
"103",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",23,-76,67,NA,"delta","~48.5 weeks",NA,NA,1781,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",339.5,2
"104",235,"Voko","Retrospective cohort","22Jul2022","AZD1222 (AstraZeneca)","included","2","final","14-120","hospitalization","severe","Hungary","18-64 years","18-64 years",76.2,70.6,80.7,NA,"delta","~47 weeks",NA,NA,2049,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",329,2
"105",235,"Voko","Retrospective cohort","22Jul2022","AZD1222 (AstraZeneca)","included","2","final","240+","hospitalization","severe","Hungary","18-64 years","18-64 years",48.8,38.2,57.6,NA,"delta","~47 weeks",NA,NA,2050,"Hungary","HUN",235,"HUN",16570,2019,"Hungary","Europe & Central Asia","High income",3,"Europe",2020-12-28,2021-06-05,NA,2020-12-23,2020-12-23,5,164,NA,"before jan/2021","Jun-Aug/2021","<180","yes","yes","no",2022-07-22,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",329,2
"106",247,"Kirsebom","Test-negative case-control","12Dec2022","AZD1222 (AstraZeneca)","included","2","final","175+","hospitalization","severe","UK",">= 65 years",">= 65 years",73.4,70.4,76.2,"delta","delta","~44.5 weeks",NA,NA,2186,"UK","GBR",247,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",311.5,1
"107",259,"Tsundue","Prospective cohort","24May2022","AZD1222 (Covishield)","included","2","final","14+","shortness of breath/use of supplemental oxygen, hospitalization or death","severe","India","residents of congregate living facilities","general pop",99,90,99.8,NA,"delta","13 weeks",NA,NA,2272,"India","IND",259,"IND",2070,2019,"India","South Asia","Lower middle income",1,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,342,NA,"jan/2021","Dec/2021 +","270-359","yes","yes","no",2022-05-24,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",91,1
"108",310,"Penayo","Test-negative case-control","01Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",83,66.3,91.5,NA,"delta","~33 weeks",NA,NA,2614,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",231,1
"109",311,"Monge","Case cohort","02Sept2022","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization","severe","Spain","50-59 years","50-59 years",96,93,98,NA,"delta","~21 weeks",NA,NA,2636,"Spain","ESP",311,"ESP",30370,2019,"Spain","Europe & Central Asia","High income",4,"Europe",2021-01-04,2021-07-04,2021-08-31,2020-12-30,2020-12-30,5,186,244,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-09-02,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",147,1
"110",345,"Clemens","Test-negative case-control","13Oct2022","AZD1222 (AstraZeneca)","included","2","final","14+","severe disease","severe","Brazil","18-60 years","18-60 years",100,44.3,100,NA,"delta","~12.5 weeks",NA,NA,2927,"Brazil","BRA",345,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2022-10-13,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",87.5,1
"111",366,"Battacharya","Test-negative case-control","06Jan2023","AZD1222 (Covishield)","included","2","final","7+","hospitalization with symptoms of pulmonary disease","severe","India",">=18 years","general pop",79,53.1,81,NA,"delta","~22 weeks",NA,NA,3164,"India","IND",366,"IND",2070,2019,"India","South Asia","Lower middle income",1,"Asia",2021-01-16,2021-12-24,NA,2021-01-16,2021-01-16,0,342,NA,"jan/2021","Dec/2021 +","270-359","yes","yes","no",2023-01-06,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",154,1
"112",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",71,27,89,NA,"delta","~32 weeks",NA,NA,3537,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",224,1
"113",420,"Irala","Test-negative case-control","15Sep2023","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",83.2,67.8,91.9,NA,"delta","~37 weeks",NA,NA,3568,"Paraguay","PRY",420,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"feb/2021","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",259,1
"114",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","<91","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",81.1,78.4,83.5,NA,"delta","~33 weeks",NA,NA,3596,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",231,4
"115",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","141+","hospitalization with ARI","severe","Mexico",">=65 years",">=65 years",70.5,64.2,75.8,NA,"delta","~33 weeks",NA,NA,3597,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",231,4
"116",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","<91","severe disease","severe","Mexico",">=65 years",">=65 years",85.3,82.8,87.5,NA,"delta","~33 weeks",NA,NA,3598,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",231,4
"117",426,"Hernandez-Avila","Test-negative case-control","19Oct2023","AZD1222 (AstraZeneca)","excluded","2","final","141+","severe disease","severe","Mexico",">=65 years",">=65 years",73.5,66.5,79.1,NA,"delta","~33 weeks",NA,NA,3599,"Mexico","MEX",426,"MEX",9860,2019,"Mexico","Latin America & Caribbean","Upper middle income",3,"North America",2020-12-27,2021-10-18,NA,2020-12-24,2020-12-24,3,298,NA,"before jan/2021","Sep-Nov/2021","270-359","yes","yes","no",2023-10-19,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","delta","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",231,4
"118",151,"Collie","Test-negative case-control","29Dec2021","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","Hospitalization","severe","South Africa",">= 18 years","general pop",70,62,76,NA,"omicron","~24 weeks",NA,NA,1295,"South Africa","ZAF",151,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"feb/2021","not reached","not reached","yes","no","no",2021-12-29,"severe","2021 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",168,1
"119",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7+","hospitalization","severe","USA","hospital admissions","general pop",62,53,69,"omicron","omicron","~47 weeks",NA,NA,1390,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",329,3
"120",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","7 to <3 months","hospitalization","severe","USA","hospital admissions","general pop",68,48,80,"omicron","omicron","~47 weeks",NA,NA,1391,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",329,3
"121",165,"Tartof","Test-negative case-control","22Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final",">=9 months","Hospitalization","severe","USA","hospital admissions","general pop",41,21,55,"omicron","omicron","~47 weeks",NA,NA,1392,"USA","USA",165,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-22,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",329,3
"122",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","1-6 months","severe, critical or fatal disease","severe","Qatar",">= 18 years","general pop",70.4,45,85,"omicron","omicron","~58 weeks",NA,NA,1535,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",406,2
"123",179,"Chemaitelly","Test-negative case-control","02Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=7 months","severe, critical or fatal disease","severe","Qatar",">= 18 years","general pop",77.5,67.8,84.3,"omicron","omicron","~58 weeks",NA,NA,1536,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",406,2
"124",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",46,28,60,NA,"omicron","~54 weeks",NA,NA,1622,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",378,2
"125",194,"Smid","Retrospective cohort","15Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",34,24,42,NA,"omicron","~54 weeks",NA,NA,1624,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",378,2
"126",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",91,83,95,NA,"omicron","~56 weeks",NA,NA,1784,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",392,2
"127",203,"Baum","Retrospective cohort","05Nov2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",58,48,66,NA,"omicron","~56 weeks",NA,NA,1785,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",392,2
"128",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",96.8,71.1,99.6,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,1814,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",308,3
"129",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",76.8,58,87.1,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,1822,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",308,3
"130",207,"Altarawneh","Test-negative case-control","15Jun2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",73.5,60.5,82.2,"omicron","omicron","44 weeks",NA,NA,1830,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",308,3
"131",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-174","hospitalization with ARI","severe","UK","18-64 years","18-64 years",73.8,62.5,81.7,NA,"omicron","~43 weeks",NA,NA,1876,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",301,4
"132",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","175+","hospitalization with ARI","severe","UK","18-64 years","18-64 years",65.1,51.3,74.9,NA,"omicron","~43 weeks",NA,NA,1877,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",301,4
"133",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-174","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",87.6,79.4,92.5,NA,"omicron","~43 weeks",NA,NA,1879,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",301,4
"134",210,"Stowe","Test-negative case-control","30Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","175+","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",65.4,56.6,72.5,NA,"omicron","~43 weeks",NA,NA,1881,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",301,4
"135",215,"Hansen","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","hospitalization","severe","Denmark",">= 12 years","general pop",50.5,33.9,63,NA,"omicron","~2 weeks",NA,NA,1904,"Denmark","DNK",215,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",14,2
"136",215,"Hansen","Retrospective cohort","30Mar2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","121+","hospitalization","severe","Denmark",">= 12 years","general pop",51.6,47.2,55.6,NA,"omicron","~30 weeks",NA,NA,1905,"Denmark","DNK",215,"DNK",63020,2019,"Denmark","Europe & Central Asia","High income",4,"Europe",2021-01-01,2021-07-16,2021-09-03,2020-12-16,2020-12-16,16,212,261,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-03-30,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",210,2
"137",230,"Plumb","Test-negative case-control","12Apr2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",37.3,25.8,46.9,NA,"omicron","~55 weeks",NA,NA,1983,"USA","USA",230,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",385,1
"138",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","severe disease","severe","Brazil",">= 18 years","general pop",82.9,80.6,85,NA,"omicron","~7 weeks",NA,NA,2118,"Brazil","BRA",240,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",49,2
"139",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","severe disease","severe","Brazil",">= 18 years","general pop",82.6,80.7,84.3,NA,"omicron","~33 weeks",NA,NA,2119,"Brazil","BRA",240,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",231,2
"140",244,"Sharma","Matched case-control","27Apr2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","USA","veterans","veterans",52.9,47.8,57.6,NA,"omicron","~42 weeks",NA,NA,2176,"USA","USA",244,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-27,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",294,1
"141",272,"Adams","Prospective test-negative case control","11Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",36,21,48,"omicron BA.1, BA.2, BA.5","omicron BA.1, BA.2, BA.5","~72 weeks",NA,NA,2319,"USA","USA",272,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-11,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",504,1
"142",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","hospitalization","severe","USA",">= 18 years","general pop",54,38,65,"omicron BA.1","omicron BA.1","~70 weeks",NA,NA,2350,"USA","USA",278,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",490,4
"143",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","hospitalization","severe","USA",">= 18 years","general pop",32,16,45,"omicron BA.1","omicron BA.1","~70 weeks",NA,NA,2351,"USA","USA",278,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",490,4
"144",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","<6 months","hospitalization","severe","USA",">= 18 years","general pop",56,-2,81,"omicron BA.2","omicron BA.2","~70 weeks",NA,NA,2354,"USA","USA",278,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",490,4
"145",278,"Tartof","Test-negative case-control","07Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","hospitalization","severe","USA",">= 18 years","general pop",56,28,73,"omicron BA.2","omicron BA.2","~70 weeks",NA,NA,2355,"USA","USA",278,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-07,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",490,4
"146",299,"Risk","Retrospective cohort","16Aug2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",67,51,78,NA,"omicron","~56 weeks",NA,NA,2525,"USA","USA",299,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-16,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",392,1
"147",301,"Yan","Case-control","18Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe disease","severe","Hong Kong","18-50 years","18-50 years",73.7,54.2,84.9,NA,"omicron BA.2","~52 weeks",NA,NA,2538,"Hong Kong","HKG",301,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",364,3
"148",301,"Yan","Case-control","18Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe disease","severe","Hong Kong","51-64 years","51-64 years",84.5,72.2,91.4,NA,"omicron BA.2","~52 weeks",NA,NA,2539,"Hong Kong","HKG",301,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",364,3
"149",301,"Yan","Case-control","18Aug2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","severe disease","severe","Hong Kong",">= 65 years",">= 65 years",81.9,74.4,87.2,NA,"omicron BA.2","~52 weeks",NA,NA,2540,"Hong Kong","HKG",301,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-08-18,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",364,3
"150",310,"Penayo","Test-negative case-control","01Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",49.5,9.9,71.7,NA,"omicron","~53 weeks",NA,NA,2618,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",371,2
"151",310,"Penayo","Test-negative case-control","01Jun2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-89","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",78,-97,97.5,NA,"omicron","~11 weeks",NA,NA,2619,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",77,2
"152",316,"Collie","Test-negative case-control","14Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","14-27","hospitalization","severe","South Africa",">=18 years","general pop",80.3,62.8,89.5,NA,"omicron BA.1 or BA.2","~36 weeks",NA,NA,2656,"South Africa","ZAF",316,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"feb/2021","not reached","not reached","yes","no","no",2022-09-14,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",252,4
"153",316,"Collie","Test-negative case-control","14Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","7-8 months","hospitalization","severe","South Africa",">=18 years","general pop",38.4,16.9,54.4,NA,"omicron BA.1 or BA.2","~36 weeks",NA,NA,2657,"South Africa","ZAF",316,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"feb/2021","not reached","not reached","yes","no","no",2022-09-14,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",252,4
"154",316,"Collie","Test-negative case-control","14Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","3-4 months","hospitalization","severe","South Africa",">=18 years","general pop",47.4,19.9,65.5,NA,"omicron BA.4 or BA.5","~53 weeks",NA,NA,2658,"South Africa","ZAF",316,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"feb/2021","not reached","not reached","yes","no","no",2022-09-14,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",371,4
"155",316,"Collie","Test-negative case-control","14Sept2022","BNT162b2 (Pfizer BioNTech)","included","2","final","9+ months","hospitalization","severe","South Africa",">=18 years","general pop",19.3,6.3,30.5,NA,"omicron BA.4 or BA.5","~53 weeks",NA,NA,2659,"South Africa","ZAF",316,"ZAF",6570,2019,"South Africa","Sub-Saharan Africa","Upper middle income",3,"Africa",2021-02-19,NA,NA,2021-02-17,2021-02-17,2,NA,NA,"feb/2021","not reached","not reached","yes","no","no",2022-09-14,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",371,4
"156",324,"Link-Gelles","Test-negative case-control","05Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","hospitalization","severe","USA",">=18 years","general pop",17,7,27,NA,"omicron BA.4 or BA.5","~82 weeks",NA,NA,2722,"USA","USA",324,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-05,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",574,1
"157",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~47 weeks","hospitalization","severe","USA",">=5 years","general pop",58.8,49.3,66.5,NA,"omicron","~47 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2733,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",329,2
"158",326,"Lin","Retrospective cohort","26Sep2022","BNT162b2 (Pfizer BioNTech)","included","2","final","~60 weeks","hospitalization","severe","USA",">=5 years","general pop",29.4,50.4,76.9,NA,"omicron","~60 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2734,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",420,2
"159",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","hospitalization","severe","Hong Kong","60-79 years","60-79 years",74.6,72.1,76.8,NA,"omicron BA.2","~24 weeks",NA,NA,2811,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",168,4
"160",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","severe disease","severe","Hong Kong","60-79 years","60-79 years",77.5,65.7,85.2,NA,"omicron BA.2","~24 weeks",NA,NA,2812,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",168,4
"161",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","hospitalization","severe","Hong Kong",">=80 years",">=80 years",81,78.2,83.5,NA,"omicron BA.2","~24 weeks",NA,NA,2815,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",168,4
"162",332,"Wan","Case-control","17Oct2022","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-180","severe disease","severe","Hong Kong",">=80 years",">=80 years",82.7,62.7,92,NA,"omicron BA.2","~24 weeks",NA,NA,2816,"Hong Kong","HKG",332,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-10-17,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",168,4
"163",341,"Tartof","Test-negative case-control","25Oct2022","BNT162b2 (Pfizer BioNTech)","included","2","final",">=6 months","hospitalization for ARI","severe","USA",">=18 years","general pop",-4,-118,50,"omicron BA.4/BA.5","omicron BA.4/BA.5","~84 weeks",NA,NA,2904,"USA","USA",341,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-25,"severe","2022 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",588,1
"164",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","hospitalization","severe","Hong Kong",">=18 years","general pop",73,69.2,76.3,NA,"omicron BA.2","~32 weeks",NA,NA,3330,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",224,4
"165",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","211-240","hospitalization","severe","Hong Kong",">=18 years","general pop",46.6,40.7,51.8,NA,"omicron BA.2","~32 weeks",NA,NA,3331,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",224,4
"166",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14-30","severe disease","severe","Hong Kong",">=18 years","general pop",69.7,50,81.6,NA,"omicron BA.2","~32 weeks",NA,NA,3332,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",224,4
"167",392,"Yan","Case-control","03May2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","211-240","severe disease","severe","Hong Kong",">=18 years","general pop",71.8,47.2,84.9,NA,"omicron BA.2","~32 weeks",NA,NA,3333,"Hong Kong","HKG",392,"HKG",50480,2019,"Hong Kong SAR, China","East Asia & Pacific","High income",4,"Asia",2021-02-23,2021-08-19,2022-03-04,NA,2021-02-23,NA,177,374,"feb/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-05-03,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",224,4
"168",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","BNT162b2 (Pfizer BioNTech)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",45,1,70,NA,"omicron BA.1","~47 weeks",NA,NA,3528,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",329,1
"169",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","14-59","severe disease","severe","Scotland",">= 18 years","general pop",90.4,30.4,98.7,NA,"omicron","~7 weeks",NA,NA,2126,"UK","GBR",500,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",49,2
"170",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","BNT162b2 (Pfizer BioNTech)","included","2","final","150+","severe disease","severe","Scotland",">= 18 years","general pop",72.9,57.9,82.5,NA,"omicron","~38.5 weeks",NA,NA,2127,"UK","GBR",500,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","BioNTech/Pfizer BNT162b2","mRNA","omicron","yes",NA,"BioNTech/Pfizer BNT162b2 x 2",269.5,2
"171",159,"Tseng","Test-negative case-control","21Feb2022","mRNA-1273 (Moderna)","included","2","final","14+","Hospitalization","severe","USA",">= 18 years","general pop",84.5,23,96.9,"omicron","omicron","~47.5 weeks",NA,NA,1349,"USA","USA",159,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-02-21,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",332.5,1
"172",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final","1-6 months","severe, critical or fatal disease","severe","Qatar",">= 18 years","general pop",87.1,40.2,97.2,"omicron","omicron","~58 weeks",NA,NA,1537,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",406,2
"173",179,"Chemaitelly","Test-negative case-control","02Jun2022","mRNA-1273 (Moderna)","included","2","final",">=7 months","severe, critical or fatal disease","severe","Qatar",">= 18 years","general pop",68.4,46.1,81.5,"omicron","omicron","~58 weeks",NA,NA,1538,"Qatar","QAT",179,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-02,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",406,2
"174",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","14-74","hospitalization","severe","Czech Republic","all ages","general pop",51,-20,80,NA,"omicron","~54 weeks",NA,NA,1630,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",378,2
"175",194,"Smid","Retrospective cohort","15Oct2022","mRNA-1273 (Moderna)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",31,9,49,NA,"omicron","~54 weeks",NA,NA,1632,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",378,2
"176",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","14-90","hospitalization","severe","Finland",">= 70 years",">= 70 years",79,43,92,NA,"omicron","~56 weeks",NA,NA,1788,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",392,2
"177",203,"Baum","Retrospective cohort","05Nov2022","mRNA-1273 (Moderna)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",60,34,75,NA,"omicron","~56 weeks",NA,NA,1789,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",392,2
"178",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",88.8,-1.7,98.8,"omicron BA.1","omicron BA.1","44 weeks",NA,NA,1816,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",308,3
"179",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",84.8,47.9,95.6,"omicron BA.2","omicron BA.2","44 weeks",NA,NA,1824,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",308,3
"180",207,"Altarawneh","Test-negative case-control","15Jun2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization or death","severe","Qatar",">= 18 years","general pop",66.3,38.3,81.6,"omicron","omicron","44 weeks",NA,NA,1832,"Qatar","QAT",207,"QAT",65700,2019,"Qatar","Middle East & North Africa","High income",4,"Asia",2021-01-28,2021-05-31,2021-08-16,NA,2021-01-28,NA,123,200,"jan/2021","before Jun/2021","<180","yes","yes","yes",2022-06-15,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",308,3
"181",230,"Plumb","Test-negative case-control","12Apr2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA","hospitalized adults","general pop",35.9,21.7,47.4,NA,"omicron","~55 weeks",NA,NA,1984,"USA","USA",230,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-12,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",385,1
"182",244,"Sharma","Matched case-control","27Apr2022","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","USA","veterans","veterans",66.7,61.4,71.6,NA,"omicron","~42 weeks",NA,NA,2179,"USA","USA",244,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-04-27,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",294,1
"183",272,"Adams","Prospective test-negative case control","11Oct2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",41,25,54,"omicron BA.1, BA.2, BA.5","omicron BA.1, BA.2, BA.5","~72 weeks",NA,NA,2320,"USA","USA",272,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-11,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",504,1
"184",299,"Risk","Retrospective cohort","16Aug2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization","severe","USA",">= 18 years","general pop",79,63,88,NA,"omicron","~56 weeks",NA,NA,2528,"USA","USA",299,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-08-16,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",392,1
"185",310,"Penayo","Test-negative case-control","01Jun2022","mRNA-1273 (Moderna)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",42.1,-105.4,83.7,NA,"omicron","~52 weeks",NA,NA,2620,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",364,1
"186",324,"Link-Gelles","Test-negative case-control","05Oct2022","mRNA-1273 (Moderna)","included","2","final","150+","hospitalization","severe","USA",">=18 years","general pop",28,17,38,NA,"omicron BA.4 or BA.5","~82 weeks",NA,NA,2725,"USA","USA",324,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-10-05,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",574,1
"187",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~46 weeks","hospitalization","severe","USA",">=5 years","general pop",64.7,57.2,70.9,NA,"omicron","~46 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2739,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",322,2
"188",326,"Lin","Retrospective cohort","26Sep2022","mRNA-1273 (Moderna)","included","2","final","~59 weeks","hospitalization","severe","USA",">=5 years","general pop",61.5,49.6,70.6,NA,"omicron","~59 weeks",NA,"Persons vaccinated between July 2021 and June 2022. The study includes additional VE estimates for individuals vaccinated between December 2020 and March 2021 and between April 2021 and June 2021",2740,"USA","USA",326,"USA",66220,2019,"United States","North America","High income",4,"North America",2020-12-13,2021-05-14,NA,2020-12-14,2020-12-13,-1,152,NA,"before jan/2021","before Jun/2021","<180","yes","yes","no",2022-09-26,"severe","2022 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",413,2
"189",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","mRNA-1273 (Moderna)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",95,54,99,NA,"omicron BA.1","~25 weeks",NA,NA,3531,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Moderna mRNA-1273","mRNA","omicron","yes",NA,"Moderna mRNA-1273 x 2",175,1
"190",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","75-135","hospitalization","severe","Czech Republic","all ages","general pop",-139,-861,41,NA,"omicron","~54 weeks",NA,NA,1635,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",378,2
"191",194,"Smid","Retrospective cohort","15Oct2022","AZD1222 (AstraZeneca)","included","2","final","135+","hospitalization","severe","Czech Republic","all ages","general pop",13,-8,30,NA,"omicron","~54 weeks",NA,NA,1636,"Czech Republic","CZE",194,"CZE",22100,2019,"Czechia","Europe & Central Asia","High income",3,"Europe",2020-12-27,2021-07-16,NA,2020-12-23,2020-12-23,4,205,NA,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","no",2022-10-15,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",378,2
"192",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","91-180","hospitalization","severe","Finland",">= 70 years",">= 70 years",37,-154,85,NA,"omicron",NA,NA,NA,1791,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",NA,2
"193",203,"Baum","Retrospective cohort","05Nov2022","AZD1222 (AstraZeneca)","excluded","2","final","181+","hospitalization","severe","Finland",">= 70 years",">= 70 years",51,12,73,NA,"omicron","~56 weeks",NA,NA,1792,"Finland","FIN",203,"FIN",49950,2019,"Finland","Europe & Central Asia","High income",4,"Europe",2021-01-17,2021-08-15,2021-10-31,2020-12-23,2020-12-23,25,235,312,"before jan/2021","Jun-Aug/2021","180-269","yes","yes","yes",2022-11-05,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",392,2
"194",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","2","final","14-174","hospitalization with ARI","severe","UK","18-64 years","18-64 years",59,31.9,75.3,NA,"omicron","~43 weeks",NA,NA,1883,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",301,4
"195",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","2","final","175+","hospitalization with ARI","severe","UK","18-64 years","18-64 years",53,41.7,62,NA,"omicron","~43 weeks",NA,NA,1884,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",301,4
"196",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","2","final","14-174","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",71.2,50,83.4,NA,"omicron","~43 weeks",NA,NA,1886,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",301,4
"197",210,"Stowe","Test-negative case-control","30Sep2022","AZD1222 (AstraZeneca)","included","2","final","175+","hospitalization with ARI","severe","UK",">= 65 years",">= 65 years",53.1,43.4,61.2,NA,"omicron","~43 weeks",NA,NA,1887,"UK","GBR",210,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-09-30,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",301,4
"198",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","14-59","severe disease","severe","Brazil",">= 18 years","general pop",77.1,72.9,80.6,NA,"omicron","~7 weeks",NA,NA,2122,"Brazil","BRA",240,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",49,2
"199",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","150+","severe disease","severe","Brazil",">= 18 years","general pop",67.8,66.7,69,NA,"omicron","~36 weeks",NA,NA,2123,"Brazil","BRA",240,"BRA",9410,2019,"Brazil","Latin America & Caribbean","Upper middle income",3,"South America",2021-01-19,2021-09-24,2022-02-05,2021-01-17,2021-01-17,2,250,384,"jan/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",252,2
"200",247,"Kirsebom","Test-negative case-control","12Dec2022","AZD1222 (AstraZeneca)","included","2","final","175+","hospitalization","severe","UK",">= 65 years",">= 65 years",61,49.8,69.7,"omicron","omicron","~44.5 weeks",NA,NA,2185,"UK","GBR",247,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2022-12-12,"severe","2022 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",311.5,1
"201",310,"Penayo","Test-negative case-control","01Jun2022","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization with SARI","severe","Paraguay",">=18 years","general pop",10.1,-31,38.3,NA,"omicron","~48 weeks",NA,NA,2621,"Paraguay","PRY",310,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"feb/2021","Dec/2021 +","270-359","yes","yes","no",2022-06-01,"severe","2022 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",336,1
"202",396,"Park","Retrospective cohort","15May2023","AZD1222 (AstraZeneca)","included","2","final","14+","critical infection","severe","South Korea",">=60 years",">=60 years",72,70,74,NA,"omicron BA.1, BA.2, BA.4/BA.5","~80 weeks",NA,NA,3359,"South Korea","KOR",396,"KOR",33830,2019,"Korea, Rep.","East Asia & Pacific","High income",4,"Asia",2021-02-26,2021-09-15,2021-10-25,2021-02-26,2021-02-26,0,201,241,"feb/2021","Sep-Nov/2021","180-269","yes","yes","yes",2023-05-15,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",560,1
"203",418,"Paternina-Caicedo","Test-negative case-control","09Sep2023","AZD1222 (AstraZeneca)","excluded","2","final","14+","hospitalization","severe","Colombia",">=5 years","general pop",10,-78,55,NA,"omicron BA.1","~43 weeks",NA,NA,3522,"Colombia","COL",418,"COL",6630,2019,"Colombia","Latin America & Caribbean","Upper middle income",3,"South America",2021-02-18,2021-10-26,2022-07-29,2021-02-17,2021-02-17,1,251,527,"feb/2021","Sep-Nov/2021","180-269","yes","yes","no",2023-09-09,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",301,1
"204",420,"Irala","Test-negative case-control","15Sep2023","AZD1222 (AstraZeneca)","included","2","final","14+","hospitalization due to SARI","severe","Paraguay",">=5 years","general pop",10,-31.3,38.2,NA,"omicron BA.1","~52 weeks",NA,NA,3563,"Paraguay","PRY",420,"PRY",5950,2019,"Paraguay","Latin America & Caribbean","Upper middle income",2,"South America",2021-02-23,2021-12-10,NA,2021-02-22,2021-02-22,1,291,NA,"feb/2021","Dec/2021 +","270-359","yes","yes","no",2023-09-15,"severe","2023 (Jul-Dec)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",364,1
"205",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","60-149","severe disease","severe","Scotland",">= 18 years","general pop",78.8,31.8,93.4,NA,"omicron","~19 weeks",NA,NA,2130,"UK","GBR",500,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",133,2
"206",240,"Cerqueira-Silva","Test-negative case-control","11Jan2023","AZD1222 (AstraZeneca)","included","2","final","150+","severe disease","severe","Scotland",">= 18 years","general pop",52.8,33.3,66.7,NA,"omicron","~35.5 weeks",NA,NA,2131,"UK","GBR",500,"GBR",43240,2019,"United Kingdom","Europe & Central Asia","High income",4,"Europe",2021-01-10,2021-06-04,2021-12-23,2020-12-21,2020-12-21,20,165,367,"before jan/2021","Jun-Aug/2021","<180","yes","yes","yes",2023-01-11,"severe","2023 (Jan-Jun)","Oxford/AstraZeneca ChAdOx1-S","Vectored","omicron","yes",NA,"Oxford/AstraZeneca ChAdOx1-S x 2",248.5,2
